As a hormone receptor coactivator, there was accumulative evidence showed that the upregulated expression of AIB1 cause resistance of endocrine therapy in hormone-dependent tumors, especially in tamoxifen resistance of breast cancer. Here, NCOA3 is linked to breast carcinoma.